Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCapital Bluecross CUP gene-expression Coverage Upd…
    Ask Trek AI about this page
    RetiredCapital BluecrossPolicy MP 2.245

    Gene expression–based assays for cancers of unknown primary (CUP)

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.245 alerts

    Get alerted when Policy MP 2.245 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of gene expression and comprehensive genomic profiling tests used to identify the tissue/site of origin for cancers of unknown primary and to guide treatment selection. It applies to Capital BlueCross-administered programs and products as described in the policy.

    Policy Summary
    PayerCapital Bluecross
    PolicyGene expression–based assays for cancers of unknown primary (CUP)
    Policy CodePolicy MP 2.245
    Change TypeRetirementinvestigational clarification
    Effective DateJul 1, 2026
    Last ReviewJul 11, 2025
    Next Review Date
    Key ActionFollow product-specific prior authorization and coding guidance when requesting coverage; tests are investigational for evaluating site of origin and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    Policy marked as RETIRED with effective date 7/1/2026.

    Gene expression and/or comprehensive genomic profiling is considered investigational to evaluate site of origin of a tumor of unknown primary, to distinguish primary from metastatic tumor, or to guide treatment selection.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~3%CUPs in U.S.
    70%CUPs that are adenocarcinomas
    80%Poor prognosis (3–6 mo)
    20%Patients with features guiding treatment
    2RCTs on clinical utility
    92genes (CancerTYPE ID)

    Coverage Determinations

    Not medically necessary / Investigational

    Policy coverage stance

    Investigational: Gene expression and/or comprehensive genomic profiling is considered investigational to evaluate the site of origin of a tumor of unknown primary, to distinguish a primary from a metastatic tumor, or to guide treatment selection.

    Insufficient evidence to conclude benefit on health outcomes.

    Not established as clinically beneficial / investigational

    Coverage stance and supporting rationale

    Policy conclusion: The evidence is insufficient to determine that gene expression profiling to identify tissue of origin improves net health outcome for cancers of unknown primary.

    Based on clinical validity data showing concordance but randomized controlled trials did not demonstrate survival benefit when treatment was guided by molecular site-of-origin results.

    The United States Food and Drug Administration clearance for the PathWork® Tissue of Origin Test includes explicit limitations on intended use. The FDA noted that the test is not intended to establish the origin of tumors that cannot be diagnosed according to current clinical and pathologic practice (for example, cancers of unknown primary).

    The FDA clearance also states that the PathWork® Tissue of Origin Test is not intended to subclassify or modify the classification of tumors diagnosable by current clinical and pathologic practice, nor is it intended to predict disease course, survival, treatment efficacy, or to distinguish a primary tumor from a metastatic tumor. The clearance warns that tumor types missing from the PathWork database may produce indeterminate or misclassified results.

    Use of gene expression profiling to identify tissue of origin, to distinguish a primary tumor from a metastatic lesion, or to guide treatment selection is considered investigational. The policy concludes there is insufficient evidence that these molecular assays improve health outcomes for patients with cancers of unknown primary.

    The body of evidence includes clinical validity studies reporting generally high concordance (often in the 80%–90% range) with reference standards, and two randomized controlled trials that evaluated clinical utility. The RCTs did not demonstrate a survival benefit when treatment decisions were guided by molecular site-of-origin results. Because reference standards are imperfect and RCTs failed to show improved outcomes, the evidence is insufficient to conclude that gene expression profiling improves net health outcome.

    Intended use to determine tissue of origin in cancers of unknown primary — clinical validity vs utility

    Intended use and interpretation considerations

    Intended use: These assays are intended to provide a suggested tissue/site of origin for cancers of unknown primary by comparing tumor RNA expression patterns to reference databases.

    Clinical validity studies report high concordance with reference standards, but the reference standards are imperfect.

    Clinical utility note: Randomized controlled trials to date did not demonstrate a survival benefit when treatment was guided by molecularly determined site-of-origin results; therefore clinical utility remains unproven.

    If more site-specific therapies become available in the future, utility could change, but current evidence is insufficient to conclude improved net health outcomes.

    Regulatory / test limitations: FDA clearance for the PathWork/ Tissue of Origin test includes explicit limitations: it is not intended to establish origin for tumors that cannot be diagnosed by current clinical and pathologic practice, not intended to predict disease course, survival, or treatment efficacy, and tumor types not in the database may lead to indeterminate or misclassified results.

    Procedure Codes and Test Descriptions

    Tests described (no billing codes listed)mixed
    No codes listed
    Procedure codes mentioned / investigational listCPTNot Covered
    0174Uprocedure code referenced in policy history and coding updates
    0019Uprocedure code removed from policy (historical reference)
    81599unlisted molecular pathology procedure code (added historically)
    Examples — Genes assayed (selected tests)
    Vyant Bio (Tissue of Origin)Oligonucleotide microarray platform; approximately 2000 genes assayed
    CancerTYPE ID (Biotheranostics)RT-qPCR platform; 92 genes assayed
    Context/SourceValues adapted from Table 1 listing tests and genes assayed in the policy (Agwa et al. 2013)
    Numeric examples — Genes assayed
    Example gene counts~2000 genes (Tissue of Origin) and 92 genes (CancerTYPE ID)
    Tissue of Origin (historical)Listed as 2000 genes in the policy table

    Provider Responsibilities and Documentation

    Prior Authorization

    Program/product prior-authorization varies by product

    Applicability of this policy to prior-authorization requirements varies by program and product; follow the product‑specific ordering and prior‑authorization pathways (for example, FEP PPO members should be referred to the FEP Medical Policy Manual).

    • Follow product-specific prior-authorization and ordering pathways as described in Section II (Product variations).
    • Example: FEP PPO — refer to the FEP Medical Policy Manual link provided in the policy.
    Prior Authorization

    Investigational procedure codes affect prior authorization

    Specific procedure codes are identified in the policy as investigational when used to report gene expression testing for cancer of unknown primary; follow the coding guidance in Section VII when seeking prior authorization or billing.

    • Codes listed in the coding section are investigational for reporting gene expression testing for CUP; consult the policy's coding table before submitting authorization requests.

    Services Not Covered

    Gene expression–based assays and comprehensive genomic profiling to determine tumor site of origin or to direct therapy in cancers of unknown primary are considered investigational and not covered. The policy explicitly states that these tests are investigational for evaluating site of origin, distinguishing primary versus metastatic disease, or guiding treatment selection, and identifies procedure codes that are investigational when used for this indication.

    Per the policy coding and evidence assessment, gene expression tests for cancer of unknown primary are considered investigational. The coding section lists procedure codes that are investigational when used to report gene expression testing for CUP, and the evidence base is judged insufficient to support clinical utility.

    Clinical Background

    Cancers of unknown primary (CUP) are metastatic malignancies in which the primary tumor site cannot be identified. CUPs account for approximately ~3% of cancers in the U.S. Most CUPs are adenocarcinomas (about 70%); other histologies include neuroendocrine tumors (~1%), squamous cell carcinoma (~5%), and poorly differentiated cancers (~20%–25%). Standard diagnostic evaluation includes imaging and detailed pathology with immunohistochemical (IHC) panels to narrow the differential, but a definitive primary is not always found. The prognosis for many patients with CUP is poor, and the goal of molecular tissue-of-origin testing is to identify a likely primary to guide therapy; however, evidence does not demonstrate improved outcomes with these tests.

    Key Definitions

    CUP — definition and context
    DefinitionCancers of unknown primary (CUPs) are metastatic tumors for which the primary site cannot be identified; they comprise approximately 3% of U.S. cancers.
    Common histologiesMost CUPs are adenocarcinomas or undifferentiated tumors; other types include squamous carcinomas, melanoma, sarcoma, and neuroendocrine tumors.
    Typical diagnostic workupConventional methods to aid identification include history and physical, CT scans of chest/abdomen/pelvis, routine labs, targeted evaluation, and biopsy with pathology.
    IHC — immunohistochemical analysis
    DefinitionImmunohistochemical (IHC) analysis is a pathology technique that identifies antigens on tumors to help classify tumor type and narrow a differential diagnosis.
    Utility
    Policy Summary
    PayerCapital Bluecross
    PolicyGene expression–based assays for cancers of unknown primary (CUP)
    Policy CodePolicy MP 2.245
    Change TypeRetirementinvestigational clarification
    Effective DateJul 1, 2026
    Last ReviewJul 11, 2025
    Next Review Date
    Key ActionFollow product-specific prior authorization and coding guidance when requesting coverage; tests are investigational for evaluating site of origin and may be denied.
    SourceLink
    On This Page
    Coverage DeterminationsProcedure Codes and Test DescriptionsProvider Responsibilities and DocumentationServices Not CoveredClinical BackgroundKey DefinitionsMember Eligibility and Preconditions

    Laboratory-developed test versions are available under CLIA; labs must be CLIA-licensed for high-complexity testing.

    CancerTYPE IDListed as 92 genes in the policy table
  1. Prior authorization requests should reference the policy's coding guidance to ensure alignment with product rules.
  2. Denial Risk

    Investigational status may lead to denial

    Gene expression and comprehensive genomic profiling for evaluating site of origin, distinguishing primary from metastatic tumor, or guiding treatment selection is considered investigational and may be denied; providers should not assume coverage without prior authorization and benefit verification.

    • The policy statement classifies these uses as investigational due to insufficient evidence of benefit.
    • Use may be denied on the basis that the procedure is investigational for CUP indications.
    Billing Rule

    Billing risk — investigational code use for CUP

    The coding section lists specific procedure codes as investigational for gene expression testing in CUP; use of these codes for that indication is subject to the policy's investigational determination and may be denied or rejected.

    • Listed procedure codes are investigational when used to report gene expression testing for cancer of unknown primary.
    • Verify coding intent and member benefits before submitting claims.
    Documentation Required

    Document the specific gene expression test and clinical rationale

    Documentation submitted with test orders or authorization requests should identify the specific gene expression profiling test used (see Table 1 for test names and platforms) and include supporting clinical information about the cancer of unknown primary.

    • Specify the exact test name and platform (e.g., Vyant Bio Tissue of Origin — oligonucleotide microarray; CancerTYPE ID — RT‑qPCR) as listed in Table 1.
    • Include clinical details supporting the CUP diagnosis and rationale for testing.
    Documentation Required

    Lab and coding documentation requirements (CLIA, investigational codes)

    Laboratory documentation must demonstrate that laboratory‑developed tests are performed in CLIA‑licensed labs meeting high‑complexity testing standards; the policy also notes procedure codes identified as investigational in the coding section.

    • Laboratory‑developed tests must meet CLIA high‑complexity standards and be performed in CLIA‑licensed laboratories.
    • Refer to the policy's coding section for procedure codes designated investigational for CUP.
    Denial Risk

    Tests for site‑of‑origin or treatment guidance are investigational

    Tests that use gene expression profiling to evaluate site of origin, to distinguish primary from metastatic tumor, or to guide treatment selection are considered investigational and are not supported by the policy; expect prior‑authorization denial or claim denial for these indications.

    • The policy explicitly states these uses are investigational with insufficient evidence of benefit.
    • Providers should document rationale but anticipate noncoverage unless benefit specifics differ by product.
    Billing Rule

    Investigational procedure codes for CUP — confirm before use

    The policy’s coding section states that the procedure codes listed there are investigational when used to report gene expression testing for cancer of unknown primary; confirm code applicability and member benefits before ordering or billing.

    • Procedure codes in Section VII are investigational for CUP gene expression testing.
    • Confirm coding intent and authorization requirements to avoid denials.
    Note
    Note

    Recommend formal genetic counseling when genetic testing is considered

    When genetic testing is pursued, the policy recommends formal genetic counseling performed by an individual with expertise in genetic medicine and testing methods; include evidence of counseling when relevant.

    • Genetic counseling should be provided by someone experienced in genetic medicine and testing methods.
    • Counseling may alter testing decisions and reduce inappropriate testing; document counseling in the medical record.
    Prior Authorization

    Follow product‑specific ordering and authorization pathways

    Applicability of ordering and authorization pathways varies by program/product; follow the product‑specific ordering and authorization pathways described in Section II and related product materials.

    • Product variations may change prior‑authorization or benefit rules; check the member’s program documentation.
    • Example: FEP PPO members are directed to the FEP Medical Policy Manual.
    IHC can usually distinguish epithelial tumors from melanoma or sarcoma and detailed cytokeratin panels may further classify carcinomas, though overlap exists.
    Role in CUP evaluationResults of IHC may provide a narrow differential of possible tumor origins but do not necessarily give a definitive answer.
    Laboratory‑developed test (LDT) — definition and regulatory context
    DefinitionLaboratory-developed test (LDT): a clinical laboratory–developed and validated test offered as a laboratory service; such tests must meet CLIA regulatory standards and be performed in laboratories licensed for high-complexity testing.
    Regulatory noteThe policy notes CancerTYPE ID is available under CLIA; historically the FDA has not required regulatory review for the LDT version.
    LimitationsLDTs are subject to CLIA requirements rather than FDA clearance unless FDA elects to review; laboratories must be CLIA-licensed for high-complexity testing to offer these assays.
    RT-qPCR — real-time quantitative PCR
    DefinitionRT-qPCR (real-time quantitative polymerase chain reaction): a PCR-based platform used for quantitative measurement of RNA expression; CancerTYPE ID in the policy is described as RT-qPCR–based.
    Policy exampleCancerTYPE ID is specifically identified in the policy table as using RT-qPCR and assaying 92 genes.
    Relation to gene expression profilingRT-qPCR is one of the platforms (alongside oligonucleotide microarray) used for gene expression–based tissue‑of‑origin assays discussed in the policy.